Cargando…
Advancements in the radiooncological Treatment of High-risk Prostate Cancer: A Quarter Century of Achievements
BACKGROUND: The aim of the study was to evaluate the development of treatment of primary high-risk prostate cancer in regards to biochemical no evidence of disease (bNED), acute and late gastrointestinal (GI) and genitourinary (GU) side effects. PATIENTS AND METHODS: Primary high-risk prostate cance...
Autores principales: | Moll, Matthias, Herrmann, Harald, Zaharie, Alexandru, Goldner, Gregor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400444/ https://www.ncbi.nlm.nih.gov/pubmed/35502906 http://dx.doi.org/10.2478/raon-2022-0018 |
Ejemplares similares
-
Clinical outcome in metastatic prostate cancer after primary radiotherapy
por: Moll, Matthias, et al.
Publicado: (2022) -
Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?
por: Hautmann, Matthias G, et al.
Publicado: (2011) -
Biochemical control after adjuvant radiation therapy for prostate cancer: a unicentric, retrospective analysis
por: Zaharie, Alexandru-Teodor, et al.
Publicado: (2021) -
Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects
por: Moll, Matthias, et al.
Publicado: (2020) -
Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
por: Moll, Matthias, et al.
Publicado: (2021)